Details
This analysis assessed the risk of angioedema following initiation of treatment with angiotensin converting enzyme (ACE) inhibitors or beta blockers using data from 2018 to 2022 in the Sentinel Distributed Database. This is a follow up to a previous analysis that estimates changes in healthcare utilization in three periods throughout the pandemic using the Merativeā¢ MarketScanĀ® Research Databases.
The study period includes data from January 1, 2018 through June 30, 2022. We distributed this request to five Sentinel Data Partners on October 24, 2023.
The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.